Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient

Published:2024-11 Issue: Volume:86 Page:101116
ISSN:2590-0412
Container-title:Respiratory Medicine and Research
language:en
Short-container-title:Respiratory Medicine and Research

Author:

Pons-Tostivint Elvire^ORCID,Hulo Pauline,Sagan Christine,Papazyan Thomas,Herbreteau Guillaume,Denis Marc

Publisher

Elsevier BV

Reference5 articles.

1. Overcoming therapy resistance in EGFR-mutant lung cancer;Passaro;Nat Cancer,2021

2. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer;Chmielecki;Nat Commun,2023

3. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M;Thress;Nat Med,2015

4. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers;Choudhury;J Thorac Oncol,2023

5. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Hendriks;Ann Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP